Close Menu

NEW YORK (GenomeWeb) – Epigenomics today reported a 102 percent increase in 2016 revenues on strong sales of its Epi proColon blood-based colorectal cancer screening test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.